Sei Investments Co. Sells 307,031 Shares of Grifols, S.A. (NASDAQ:GRFS)

Sei Investments Co. reduced its position in Grifols, S.A. (NASDAQ:GRFS) by 14.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,862,930 shares of the biotechnology company’s stock after selling 307,031 shares during the period. Sei Investments Co.’s holdings in Grifols were worth $13,860,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Chesapeake Capital Corp IL raised its stake in shares of Grifols by 49.3% in the fourth quarter. Chesapeake Capital Corp IL now owns 24,638 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 8,138 shares during the last quarter. Corient Private Wealth LLC raised its position in Grifols by 11.0% in the 4th quarter. Corient Private Wealth LLC now owns 50,883 shares of the biotechnology company’s stock worth $379,000 after buying an additional 5,040 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in Grifols during the 4th quarter valued at about $77,000. Brandes Investment Partners LP boosted its holdings in shares of Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company’s stock valued at $152,491,000 after acquiring an additional 592,096 shares during the last quarter. Finally, Fore Capital LLC bought a new stake in shares of Grifols in the fourth quarter worth approximately $967,000.

Analysts Set New Price Targets

Separately, Morgan Stanley assumed coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Stock Performance

Shares of GRFS opened at $7.27 on Friday. The firm has a market capitalization of $5.00 billion, a P/E ratio of 6.21 and a beta of 0.35. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a one year low of $5.79 and a one year high of $9.96. The business has a fifty day moving average of $7.56 and a 200 day moving average of $8.05.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.